Related Experiment Video
Updated: May 14, 2026
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
Published on: January 15, 2010
PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target
Abdullah Shafique Ahmad1, Takayuki Maruyama, Shuh Narumiya
1Department of Anesthesiology, University of Florida College of Medicine, PO Box 100159, Gainesville, FL 32610-0254, USA.
Abstract:
Recent experimental data on Parkinson's disease (PD) predicts the critical role of inflammation in the progression of neurodegeneration and the promising preventive effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Previous studies suggest that NSAIDs minimize cyclooxygenase-2 (COX-2) activity and thereby attenuate free radical generation. Prostaglandin E2 (PGE2) is an important product of COX activity and plays an important role in various physiologic and pathophysiologic conditions through its EP receptors (EP1-EP4). Part of the toxic effect of PGE2 in the central nervous system has been reported to be through the EP1 receptor; however, the effect of the EP1 receptor in PD remains elusive. Therefore, in our pursuit to determine if deletion of the PGE2 EP1 receptor will attenuate 6-hydroxy dopamine (6-OHDA)-induced Parkinsonism, mice were given a unilateral 6-OHDA injection into the medial forebrain bundle. We found that apomorphine-induced contralateral rotations were significantly attenuated in the 6-OHDA-lesioned EP1(-/-) mice compared with the 6-OHDA-lesioned WT mice. Quantitative analysis showed significant protection of dopaminergic neurons in the substantia nigra pars compacta of the 6-OHDA-lesioned EP1(-/-) mice. To the best of our knowledge, this is the first in vivo study to implicate the PGE2 EP1 receptor in toxin-induced Parkinsonism. We propose the PGE2 EP1 receptor as a new target to better understand some of the mechanisms leading to PD.
Insights
Deleting the Prostaglandin E2 (PGE2) EP1 receptor protected against Parkinson's disease (PD) symptoms in mice. This finding suggests the EP1 receptor is a potential new target for PD therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Inflammation research
Background:
- Inflammation is implicated in Parkinson's disease (PD) progression.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) may offer neuroprotection by reducing cyclooxygenase-2 (COX-2) activity and free radical generation.
- Prostaglandin E2 (PGE2), a COX product, exerts effects via EP receptors (EP1-EP4), with EP1 linked to neurotoxicity.
Purpose of the Study:
- To investigate the role of the PGE2 EP1 receptor in 6-hydroxy dopamine (6-OHDA)-induced Parkinsonism.
- To determine if EP1 receptor deletion attenuates neurodegeneration in a mouse model of PD.
Main Methods:
- Unilateral 6-hydroxy dopamine (6-OHDA) injections into the medial forebrain bundle of mice.
- Comparison of EP1 receptor knockout (EP1(-/-)) mice with wild-type (WT) mice.
- Assessment of apomorphine-induced contralateral rotations and dopaminergic neuron survival in the substantia nigra pars compacta.
Main Results:
- 6-OHDA-lesioned EP1(-/-) mice exhibited significantly attenuated apomorphine-induced contralateral rotations compared to 6-OHDA-lesioned WT mice.
- Quantitative analysis revealed significant protection of dopaminergic neurons in the substantia nigra pars compacta of EP1(-/-) mice.
- This study provides the first in vivo evidence implicating the PGE2 EP1 receptor in toxin-induced Parkinsonism.
Conclusions:
- The deletion of the PGE2 EP1 receptor confers significant protection against 6-OHDA-induced neurodegeneration.
- The PGE2 EP1 receptor represents a novel therapeutic target for understanding and potentially treating Parkinson's disease.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...